Researchers in Britain have developed the world’s most effective malaria vaccine, with it becoming the first to achieve the World Health Organisation-specified 75 per cent efficacy goal.
Researchers from the University of Oxford and their partners have reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated 77 per cent efficacy over 12 months of follow-up.
They hope the vaccine can be approved for use within the next two years, building on the speed and lessons learned through the rapid development of Covid-19 crisis.
Adrian Hill, who is director of the Jenner Institute, and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, also led the research behind the Oxford/AstraZeneca coronavirus vaccine.
Post Your Comments